2) Cooperate in research and development of recombinant basic fibroblast growth factor (FGF b) 1996, and obtain the national first-class medicine.
3) The chief research and development of recombinant streptokinase 1998 was approved clinically.
4) The derivative of δ 1-9(Ala 10) human interleukin 1 1 developed by the inventor and the project leader obtained the clinical approval of a class of biological products in April 2000 and the production approval in June 2003.
5) The key development projects of recombinant hirudin and ganglioside have been approved for production.
6) Since 2006, Chongqing Fujin Bio-declared three first-class biological products and 1 a 1. 1 clinical applications.
6) Chongqing Fujin Bio has applied for patents successively * * 1 1 PCT, and there are more than 30 domestic patent applications.
4. The academic research project of SME Innovation Fund of Ministry of Science and Technology (1) recombinant IFN-γ variant, 2004.438+00-2007.4, sponsored by the project. (2) Mutation breeding and high-yield strains of immunosuppressant-related strains from microorganisms, supported by the Ministry of Science and Technology, supported by the project from August 20, 2007 to Kloc-0/0.2. (3) Study on the effect of recombinant human keratinocyte factor on hepatic stellate cells, National Natural Science Foundation, 2005.6438+0-2008.438+0, the first main research. (4) Pre-clinical research on recombinant leukocyte inhibitory factor and hirulog chimeric protein, supported by the National Major Fund for New Drug Creation, 2008.438+00-20438+00.438+02. (5) Research on candidate drugs of recombinant TRAIL-FC tumor apoptosis protein, supported by the National Major Fund for New Drug Creation, 2008.438+00-438+00.5438+02. (6) Pre-clinical research on pegylated recombinant integrated interferon variants, supported by the National Major Fund for New Drug Creation, 2008.438+00-20438+00.438+02. (7) Research on PEGylated DesB30 insulin candidate drug, supported by the National Major Fund for New Drug Creation, 2008.438+00-20438+00.6438+02. (8) Study on anti-fibrosis and anti-cancer mechanism of recombinant human keratinocyte growth factor mutant, supported by Chongqing Natural Science Foundation, 2008. 1-2009. 12.